The data pertains to target groups who received seasonal influenza vaccination under Seasonal Influenza Vaccination Programmes, including the Vaccination Subsidy Scheme, the Government Vaccination Programme, the Seasonal Influenza Vaccination School Outreach Programme and the Residential Care Home Vaccination Programme.
|
Target group |
Number of vaccine recipients (% of the persons in the target group)a |
||
| 2023/24 | 2024/25 | 2025/26 (As at 30 Nov 2025) | |
|
Children of age 6 months to under 6 years |
114,600 (48.8%) | 122,300 (55.2%) | 92,000 (44.9%) |
|
Children of age 6 to under 12 years |
235,200 (68.0%) | 243,600 (73.8%) | 193,700 (61.6%) |
|
Children of age 12 to under 18 yearsb |
142,500 (40.9%) | 202,700 (56.3%) | 157,900 (46.2%) |
|
Persons of age 50 to 64 years |
349,500 (19.2%) | 465,100 (25.6%) | 366,000 (20.5%) |
|
Persons of age 65 years or above |
842,800 (51.5%) | 888,400 (51.8%) | 753,800 (42.0%) |
|
Othersc |
140,200 | 129,300 | 104,500 |
a Only where accurate population statistics available for the group.
b In 2022/23, eligible groups of Hong Kong residents are expanded to include those less than 18 years (or secondary school students) in various SIV programmes under the DH for this season.
c Eligible pregnant women, persons with chronic medical problems, healthcare workers, poultry workers, pig farmers or pig-slaughtering industry personnel.
The data pertains to elderly of age 65 years or above who received pneumococcal vaccination under Pneumococcal Vaccination Programmes, including the Vaccination Subsidy Scheme, the Government Vaccination Programme and the Residential Care Home Vaccination Programme.
.
| 2023/24 | 2024/25 | 2025/26 (as at 30 November 2025) |
|
|
Number of vaccine# recipients |
115,300& | 128,900^ | 61,800* |
|
Cumulative % among elderly population + |
41.5% | 43.8%@ | N/A |
# 23vPPV; PCV13 or PCV15
& Including 56 500 doses of 23vPPV; 50 100 doses of PCV13 and 8 700 doses of PCV15.
^ Including 68 800 doses of 23vPPV; 5 100 doses of PCV13 and 55 000 doses of PCV15.
* Including 36 800 doses of 23vPPV and 25 000 doses of PCV15.
+ Refers to the cumulative percentage of surviving elderly, among elderly population, who had received at least a dose of 23vPPV; PCV13 or PCV15 under the programmes.
@ The relevant figures are calculated based on the accumulative number of persons vaccinated (excluding those deceased) as at 28 February 2025.